NHLBI Advances Integrated Heart, Lung, Blood

Why Is NHLBI Linking Heart, Lung, Blood, and Sleep Research Together?

The National Heart, Lung, and Blood Institute, one of the largest of the National Institutes of Health, has long studied cardiovascular disease, pulmonary disorders, blood diseases, and sleep health under a single umbrella. Researchers increasingly recognize that conditions like obstructive sleep apnea, heart failure, chronic obstructive pulmonary disease, and sickle cell disease are not isolated problems — they interact through shared pathways involving inflammation, oxygen handling, vascular stress, and circadian regulation.

According to NHLBI strategic priorities published in recent years, integrated research is meant to accelerate understanding of how dysfunction in one system, such as fragmented sleep, drives downstream cardiovascular and metabolic risk. The institute supports large cohort studies, clinical trials, and basic science that cut across these traditional silos, with the goal of producing prevention strategies and therapies that address root mechanisms rather than single organ symptoms.

What Are the Public Health Stakes of Cardiopulmonary and Sleep Disease?

The U.S. Centers for Disease Control and Prevention reports that heart disease is the leading cause of death in the United States, responsible for roughly one in every five deaths. Chronic lower respiratory diseases, including COPD and asthma, also rank among the top causes of mortality. The World Health Organization similarly identifies cardiovascular disease as the world's leading cause of death globally.

Sleep disorders such as obstructive sleep apnea affect tens of millions of American adults and are widely under-diagnosed. Untreated sleep disordered breathing is associated with hypertension, atrial fibrillation, stroke, and metabolic dysfunction. Blood disorders, including sickle cell disease, contribute substantial morbidity in affected populations and have historically received less research investment relative to disease burden — a gap NHLBI strategic plans have explicitly highlighted.

How Could Integrated Research Translate Into Better Patient Care?

One practical implication of integrated heart-lung-blood-sleep research is improved screening. Patients presenting with treatment-resistant hypertension, for example, may benefit from sleep evaluation rather than additional antihypertensive therapy alone. Similarly, individuals with chronic lung disease may need cardiovascular risk reduction as part of routine pulmonary care.

NHLBI-funded investigators are also exploring how circadian biology, inflammation, and the microvasculature contribute to disease across these systems. Therapies targeting these shared pathways — including anti-inflammatory drugs, GLP-1 receptor agonists already showing cardiovascular benefit, and behavioral sleep interventions — illustrate how a unified research strategy can yield treatments with effects spanning multiple disease categories.